To demonstrate the diversity in reporting of hypoglycaemia across RCTs, the present review focuses on two treat‐to‐target trial programmes of second‐generation BI analogues, namely, the BEGIN trials, which compared insulin degludec (IDeg) with insulin glargine 100 U/mL (Gla‐100),18, 19, 20, 21, 22, 23, 24, 25, 26 and the EDITION trials, in which insulin glargine 300 U/mL (Gla‐300) and Gla‐100 were compared. Here, INS is linked to Hypoglycemia.